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Abstract 
The purpose of this study was to compare the early or late expression levels of p65, Bcl‑2, and type II myosin and the 
frequency of TUNEL‑positive nuclei in the rat masseter muscle after injection of different concentrations of botulinum 
toxin‑A (BTX‑A). We injected either 5 U or 10 U of BTX‑A into both masseter muscles of the rat. As a control group, 
the same volume of saline was injected. After 2 or 12 weeks, the animals were sacrificed. Subsequently, a biopsy and 
immunohistochemical staining of the samples were performed using a p65, Bcl‑2, or type II myosin antibody. Addi‑
tionally, a TUNEL assay and transmission electron microscopic analysis were performed. The expression of p65, Bcl‑2, 
and type II myosin increased significantly with increasing concentrations of BTX‑A at 2 weeks after BTX‑A injection 
(P < 0.05). The number of TUNEL‑positive nuclei was also significantly increased in the BTX‑A‑treated groups in com‑
parison to the saline‑treated control at 2 weeks after BTX‑A injection (P < 0.05). Elevated expression of Bcl‑2 was also 
observed in 10‑unit BTX‑A‑treated group at 12 weeks after injection (P < 0.05). At 12 weeks after injection, the number 
of enlarged mitochondria was increased, and many mitochondria displayed aberrations in cristae morphology after 
BTX‑A injection. In conclusion, BTX‑A injection into the masseter muscle increased the expression level of p65, Bcl‑2, 
and type II myosin at an early stage. The morphological changes of mitochondria were more evident at 12 weeks after 
injection.
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Background
Botulinum toxin-A (BTX-A) is a protein produced by 
bacterium Clostridium botulinum (Schiavo et  al. 1992). 
Synaptosomal-associated protein of 25  kDa (SNAP-25) 
has been regarded as the only target for BTX-A until 
recently (Rossetto et  al. 2014). BTX-A mediated SNAP-
25 proteolysis inhibits acetylcholine release from nerve 
endings (Rossetto et  al. 2014). Since the approval of its 
usage by the US Food and Drug Administration (FDA) in 
1989, BTX-A has been widely used in the field of oral and 
maxillofacial surgery for the treatment of temporoman-
dibular disorder (Kim et al. 2016) and masseteric hyper-
trophy (von Lindern et al. 2001). The therapeutic dosage 
of BTX-A has been regarded as safe with few complica-
tions (Mahant et  al. 2000). However, small amounts of 
BTX-A may enter into circulation, and its duration is not 
yet determined (Carruthers and Carruthers 1997).
Recently, new findings suggest that BTX-A may have 
antimitotic and antitumor properties (Matak and Lacko-
vic 2015). BTX-A reduces fibroblast proliferation origi-
nating from keloid scarring (Zhibo and Miaobo 2008). 
BTX-A induces apoptosis mediated by capase-3 and 
capase-7 in breast cancer cells (Bandala et  al. 2013). 
Interestingly, these fibroblasts and breast cancer cells do 
not express SNAP-25 (Matak and Lackovic 2015). BTX-A 
also activates apoptotic pathways in the prostate via sym-
pathetic nerve impairment (Gorgal et  al. 2012). Positive 
deoxynucleotidyl transferase biotin dUTP nick-end label-
ling (TUNEL) staining is increased in rat and dog pros-
tates following BTX-A injection (Doggweiler et al. 1998; 
Chuang et  al. 2006). As BTX-A is widely used for the 
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correction of strabismus, the potential for apoptosis to 
occur in the extraocular muscle following BTX-A injec-
tion has also been studied (Croes et al. 2007). The prolif-
eration zone of the mandibular condyle shows increased 
apoptosis following BTX-A injection (Kim et  al. 2008). 
Although clinical application of BTX-A has increased, 
potential induction of apoptosis in the masseter muscle 
has not been studied.
Endoplasmic reticulum (ER) stress-induced inflam-
mation is mainly mediated by Jun NH2-terminal kinase 
(JNK) (Zhang and Kaufman 2008a) and nuclear factor-
kappa B (NF-κB) (Hu et  al. 2006; Zhang and Kaufman 
2008a). Ultimately, uncontrolled and excessive ER stress 
will lead to apoptosis and cell death (Ron and Wal-
ter 2007; Zhang and Kaufman 2008b). The Bcl-2 family 
members are involved in ER stress-induced apoptosis 
(Logue et al. 2013) to the extent that apoptotic signaling 
can be modulated by regulating Bcl-2 level (Gomez et al. 
2007; Kurata et  al. 2011). In addition, overexpression 
of Bcl-2 reduces the loss of mitochondrial membrane 
potential and protects cells against ER stress-induced 
apoptosis (Heath-Engel et  al. 2008). Therefore, measur-
ing NF-κB and Bcl-2 level would be useful indicators for 
cellular apoptosis. The p65 is a family of NF-κB and the 
expression of p65 is increased by exercise-induced mus-
cle trauma (Crane et al. 2012). In addition, the dynamic 
shifts in mitochondrial morphology coincide with a num-
ber of physiological events, such as transitions between 
different respiratory states and cristae remodeling during 
apoptosis (Parra et al. 2011).
The composition of myofiber-type is changed by oxida-
tive damage (Koutakis et al. 2014). Peripheral artery dis-
ease produces myopathy and myosin type II (MYO2) and 
MYO1/2 mixed fiber are increased (Koutakis et al. 2014). 
Short-term limb immobilization induces decreased 
MYO1 and MYO2a area (Yasuda et  al. 1985). BTX-A 
injection induces increased expression of gene related to 
impaired mitochondrial biogenesis at 1  week (Mukund 
et  al. 2014). BTX-A injection to muscles increases the 
expression of proteins related to cellular stress response 
(Han et  al. 2013). As BTX-A increases stress-response 
to injected muscle, composition of MYO type will be 
changed after BTX-A injection. Actually, MYO2a com-
position is increased in the masseter muscle of pig 
after BTX-A injection (Gedrange et  al. 2013). There-
fore, MYO2a could be used as an indicator of the stress 
induced by BTX-A injection.
Serious complications such as death and seizures are 
reported after BTX-A injection, and these complica-
tions are associated with high-dose application of BTX-A 
and underlying systemic disease (Coté et  al. 2005). The 
purpose of this study was to compare the expression 
levels of MYO2a, p65 and Bcl-2 and the frequency of 
TUNEL-positive nuclei in the rat masseter muscle after 
injection of BTX-A at different concentrations. Addition-
ally, the ultrastructure of masseter muscle was studied 
using transmission electron microscopic (TEM) images.
Methods
Animals and experimental design
Male Wistar rats aged 18  weeks were purchased from 
Samtako (Seoul, Korea). They were housed individually 
at a controlled temperature (20–22 °C) and hygrometry 
(approximately 40 %) in a 12 h light: 12 h darkness cycle. 
They had free access to water. During the adaptation 
period (first week) all rats were fed ad  libitum with a 
control semi-synthetic diet (4 % lipids from soya vegetal 
oil, 74  % carbohydrates from sucrose and cornstarch, 
and 14  % proteins from casein, supplemented with 
standard vitamins and mineral mix), following classi-
cal recommendations. All diets were prepared within 
Gangneung-Wonju National University facilities. All 
groups were maintained ad libitum for 7 days receiving 
a diet similar to the adaptation diet while daily sponta-
neous intake was measured (26.1 ± 4.1 g/d, n = 30). At 
the end of the normal diet period, rats (20  weeks-old) 
were separated: the control group received a saline 
injection into both masseter muscles (group 1, n = 10), 
and the others were separated into two groups for the 
BTX injection study (n = 10 per group). All re-feeding 
diets were the same as the ad  libitum control period. 
To measure food intake all groups were individually 
housed. Group 1 was the saline-injected group. Animals 
in group 2 received a 5-unit BTX-injection to each mas-
seter muscle, and group 3 received a 10-unit BTX-injec-
tion to each masseter muscle. Half of the animals were 
sacrificed at 14  days after the injection. The other ani-
mals were sacrificed at 12 weeks after injection. All pro-
cedures were conducted according to the guidelines of 
laboratory animal care and were approved by the Gang-
neung-Wonju National University for animal research 
(GWNUA-2015-35).
TUNEL assay and immunohistochemical determination 
of p65 and Bcl‑2 in rat masseter muscle
The samples were harvested, decalcified in 5  % nitric 
acid for 5  days, and dehydrated in ethyl alcohol and 
xylene. After separation of the calvarial bones, the head 
samples were embedded in paraffin blocks. The paraf-
fin blocks were sliced into sections. The section with the 
occlusal plane area was selected. The TUNEL assay was 
performed using the DeadEnd™ fluorometric TUNEL 
system (Promega, Madison, WI, USA). The detailed pro-
cedure was consistent with the manufacturer’s protocol. 
The number of TUNEL positive nuclei in 10 random 
fields at ×400 magnification in the masseter muscle was 
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evaluated by computer-assisted image analysis. DAPI 
stain was used as a counterstaining.
To determine the level of expression of MYO2a, p65, 
and Bcl-2, immunohistochemical staining was performed 
using anti-MYO2a antibody (sc-71632: Santa Cruz Bio-
tech, Santa Cruz, CA, USA), anti-p65 antibody (sc-8008: 
Santa Cruz Biotech), and anti-Bcl-2 antibody (sc-492: 
Santa Cruz). Paraffin-embedded tissues from rat masse-
ter muscles were prepared. For antigen retrieval, sections 
were incubated in trypsin for 7  min at 37  °C. The pri-
mary antibody dilutions were as follows: p65 and BCL2 
for 1:50. The immunohistochemical procedures were 
performed as described in a previous publication. The 
negative controls were sections stained without primary 
antibodies.
Stained sections were examined in an Olympus BX51 
(Olympus, Tokyo, Japan) microscope. Digital images of 
the selected sections were captured with a digital cam-
era (DP-73; Olympus, Tokyo, Japan). The images were 
analyzed using Sigma Scan pro (SPSS, Chicago, IL). To 
quantify the immunohistochemical reaction intensity, 
the positive intensity immuno-staining in 10 random 
fields at ×100 magnification in the masseter muscle 
was evaluated by computer-assisted image analysis after 
image transformation to grayscale. The staining inten-
sity was expressed as the mean intensity value (0: lowest 
intensity, 255: highest intensity). The samples were not 
counterstained so that the absorbance would be solely 
attributable to the product of the immunohistochemical 
reaction.
Transmission electron microscopic (TEM) analysis
The specimen preparation was referred to Cheongwon 
Center, KSBI. The detailed procedure was as follows. The 
masseter muscles were cut as 1  mm ×  1  mm ×  1  mm. 
These specimens were put into 2.5  % glutaraldehyde in 
1  M PB buffer overnight. The specimens were washed 
with 0.1  M  PB buffer for 10  min three times. After 
removing supernatant solution, they were put into 1  % 
OsO4 for 1 h. The specimens were washed with 0.1 M PB 
buffer for 10 min three times, again. The specimens were 
washed with distilled water for 5  min two times. Then, 
the specimens underwent a dehydration process with 
a graded series of ethanol. The specimens were substi-
tuted with 100 % propylene oxide for 30 min two times. 
Then, the specimens were embedded in propylene oxide 
and Epon812 media. The embedded specimens were cut 
as ultra-thin Sections (70  nm thickness) using Ultra-
Microtome (ULTRACUT UCT, LEICA, installed at the 
Korea Basic Science Institute). The prepared section was 
referred to Gangneung Center, KSBI for taking a TEM 
image. The cut section was placed on a 150 mesh grid. 
The specimens were observed with JEM-2100F (JEOL, 
Japan, installed at Korea Basic Science Institute) under 
200 keV.
Statistical analysis
SPSS for Windows ver. 19 (IBM Co., Armonk, NY, USA) 
was used for statistical analysis. The differences among 
groups were evaluated by ANOVA. For post hoc tests, 
Bonferroni’s method was used. The statistical significance 
level was set at P < 0.05.
Results
The results of the TUNEL assay demonstrated that the 
number of highly fluorescent nuclei in the masseter mus-
cle was increased in the 5 U and 10 U BTX-A-treated 
groups in comparison to the saline-treated control 
group at 2  weeks after injection (Fig.  1a). The TUNEL 
assay demonstrated that the number of TUNEL-posi-
tive nuclei was significantly higher in the 10 U BTX-A-
treated group than in the saline-treated group (Fig.  1b; 
P < 0.001). The mean numbers of TUNEL-positive nuclei 
were 2.60 ± 0.55, 8.80 ± 4.21, and 16.60 ± 2.97 for the 
saline, 5 U, and 10 U BTX-A treatments, respectively. The 
post hoc test revealed differences between the groups 
treated with 10 U BTX-A and the other groups, with sig-
nificantly higher values in the 10 U BTX-A group than in 
the saline-treated control and 5 U BTX-A-treated group 
(P < 0.001 and 0.004 for the saline-treated group and the 
5 U BTX-A-treated group, respectively). However, there 
was no difference in the number of TUNEL-positive 
nuclei among groups at 12 weeks after injection (data not 
shown).
The immunohistochemical findings demonstrated 
that there was a statistically significant difference among 
groups in MYO2a expression at 2 weeks after injection. 
Both BTX-A-treated groups displayed higher MYO2a 
expression than the saline-treated group (Fig.  2a, b). 
The expression level of MYO2a was 83.61  ±  4.90, 
115.07 ± 22.77, and 125.57 ± 18.39 in the saline-treated, 
5 U BTX-treated-, and 10 U BTX-treated groups, 
respectively, at 2  weeks after injection. The difference 
among groups was statistically significantly (P = 0.006). 
In the post hoc test, the 5 U BTX-A-treated group and 
10 U BTX-A-treated group resulted in significantly 
higher values compared with the saline-treated group 
(P =  0.040 and 0.007, respectively). However, there was 
no statistically significant difference among groups in 
MYO2a expression at 12 weeks after injection (P > 0.05). 
The expression level of MYO2a was 82.79  ±  5.73, 
89.57  ±  9.14, and 98.25  ±  11.82 in saline-treated, 5 U 
BTX-treated, and 10 U BTX-treated groups, respectively, 
at 12  weeks after injection. Both BTX-A-treated groups 
displayed a similar level of MYO2a expression to the 
saline-treated group.
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The expression of p65 was significantly different among 
groups at 2 weeks after injection (Fig. 3, P = 0.001). The rel-
ative expression of p65 was increased in both BTX-treated 
groups at 2 weeks after injection. The expression level of 
p65 was 85.94 ± 4.65, 104.55 ± 8.65, and 117.94 ± 13.79 in 
the saline-treated, 5 U BTX-treated, and 10 U BTX-treated 
groups, respectively, at 2 weeks after injection. In the post 
hoc test, 5 U and 10 U BTX-A treatment resulted in sig-
nificantly higher values compared with the saline-treated 
group (P  =  0.033 and 0.001, respectively). The elevated 
p65 expression was maintained at 12  weeks after injec-
tion (Fig. 3). The expression level of p65 was 87.74 ± 5.61, 
110.31 ± 23.08, and 113.56 ± 12.41 in saline-treated, 5 U 
BTX-treated, and 10 U BTX-treated groups, respectively, 
at 12 weeks after injection. However, the difference among 
groups was not statistically significant (P > 0.05).
The expression of Bcl-2 was significantly differ-
ent among groups at 2  weeks after injection (Fig.  4, 
P = 0.001). The relative expression of Bcl-2 was increased 
in both BTX-treated groups at 2  weeks after injec-
tion. The expression level of Bcl-2 was 80.65  ±  6.07, 
113.45 ± 12.75, and 113.08 ± 15.03 in saline-treated, 5 U 
BTX-treated, and 10 U BTX-treated groups, respectively, 
at 2 weeks after injection. In the post hoc test, 5 U and 10 
U BTX-A treatment resulted in significantly higher values 
compared with the saline-treated group (P  =  0.003 for 
both groups). The elevated Bcl-2 expression was main-
tained at 12  weeks after injection (Fig.  4). The expres-
sion level of Bcl-2 was 78.20 ± 8.26, 93.92 ± 12.40, and 
120.30 ±  23.56 in saline-treated, 5 U BTX-treated, and 
10 U BTX-treated groups, respectively, at 12 weeks after 
injection. The difference among groups was statistically 
Fig. 1 The results of the TUNEL assay at 2 weeks after injection. a The number of highly fluorescent nuclei in the masseter muscle was increased in 
the 5 U and 10 U BTX‑A‑treated groups in comparison to the saline‑treated control group (original magnification ×400). DAPI staining was used as 
a counterstaining. b The TUNEL assay demonstrated that the number of TUNEL‑positive nuclei was significantly higher in the 10 U BTX‑A‑treated 
group than in the saline‑treated group (*P < 0.001)
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significant (P  =  0.005). In the post hoc test, the 10 U 
BTX-A-treated group had significantly higher values 
compared with the saline-treated group (P = 0.004).
Considering the profound myofilaments abnormalities 
observed in the masseter muscle of BTX-A-treated rats, 
the morphology of mitochondria in the muscle fibers was 
compared in TEM images. Destruction of myofibrils was 
not prominent at 2  weeks following 10 U BTX-A treat-
ment (Fig.  5). However, destruction of mitochondrial 
structure and subsequent autophagy formation were 
observed at 2 weeks after BTX-A injection. At 12 weeks 
after BTX-A injection, muscle fibers had numerous 
large mitochondria with loosely packed cristae in the 
5 U BTX-A group (Fig.  6). These mitochondria were 
interspersed between myofibrils. In addition, regional 
destruction of myofibrils was also found. This type of 
myofibril destruction was more extensive in the 10 U 
BTX-A group at 12 weeks after injection. Mitochondrial 
degeneration and myelinic figure was noticed. Many 
mitochondria showed aberrations in cristae morphology, 
and the Z line was discontinuous.
Discussion
In this study, the relative expressions of MYO2a, p65, and 
Bcl-2 were increased 2  weeks after BTX-A injection. In 
addition, regional chromatin condensation and ruptured 
mitochondrial membranes were observed with increased 
number of TUNEL positive nuclei. Elevated levels 
of MYO2a, p65, and Bcl-2 were generally decreased 
12  weeks after BTX-A injection. However, enlarged 
Fig. 2 Immunohistochemical findings of MYO2a expression. a Both BTX‑A‑treated groups displayed higher MYO2a expression than the saline‑
treated group (original magnification ×100). b The 5 U BTX‑A‑treated group and 10 U BTX‑A‑treated group had significantly higher values com‑
pared with the saline‑treated group at 2 weeks after injection (*P < 0.05)
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mitochondria and aberrations in cristae morphol-
ogy were evident in the 10 U BTX-A treatment group. 
Increasing apoptotic stress at 2 weeks after BTX-A injec-
tion might be a direct effect of the toxin on the muscle 
cells. However, enlarged mitochondria and aberrations in 
cristae morphology in the 10 U BTX-A treatment group 
at 12 weeks after injection might be due to an imbalance 
between physical loading and non-paralyzed muscle 
cells.
The composition of type II fibers is known to be 
increased after BTX-A injection into the masseter mus-
cle (Moon et al. 2015). Our study also demonstrated ele-
vated levels of MYO2a at 2 weeks after BTX-A injection. 
The composition of type II fibers increases following 
heavy resistance loading to skeletal muscles (D’Antona 
et  al. 2006). As BTX-A dose-dependently denervated 
the masseter muscle, it is expected that the number of 
paralyzed muscle cells would increase dose-depend-
ently. Accordingly, the loading to residual functional 
fibers would be increased. Interestingly, decreased food 
intake rapidly recovered following BTX-A injection in 
both rats (Moon et al. 2015) and humans (Freund et al. 
1999). As small functional fibers received heavy load, 
this should induce changes in metabolism. Aberrations 
in mitochondrial cristae morphology are accompanied 
by changes in metabolism (Parra et  al. 2011; Nasrallah 
and Horvath 2014), and together with the down-reg-
ulation of optic atrophy protein-1 or mitofusin, these 
aberrations trigger alterations of the inner mitochon-
drial membrane structures, which leads to fragmented 
Fig. 3 Immunohistochemical findings of p65 expression. a The expression of p65 was increased in both BTX‑treated groups at 2 weeks after injec‑
tion (original magnification ×100). b The 5 U BTX‑A‑treated group and 10 U BTX‑A‑treated group had significantly higher values compared with the 
saline‑treated group at 2 weeks after injection (*P < 0.05)
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mitochondria with greatly reduced oxygen consump-
tion and electrochemical potential (Chen and Chan 
2005). BTX-A irreversibly binds to the motor nerve 
endings within 90 min (Klein 2003). Consequently, the 
paralysis of the masseter muscle is evident immediately 
after BTX-A injection (Park et  al. 2015). As the effect 
of BTX-A injection lasts more than 3 months (Ma et al. 
2004), the stress from the metabolic imbalance will 
accumulate until 3 months after injection. Subsequently, 
the size of mitochondria is enlarged due to the demands 
of metabolic requirements.
Some mitochondria showed ruptured outer mem-
branes and destruction of cristae morphology at 2 weeks 
after BTX-A injection. Damaged mitochondria were 
encompassed by membranes and underwent autophagy 
formation. Some toxin actions of BTX-A might be inde-
pendent of SNAP-25 (Matak and Lacković 2015). BTX-A 
increases the apoptotic index in human prostate can-
cer cell lines that express neither SNAP-25 transcript 
nor protein (Karsenty et  al. 2009; Matak and Lacković 
2015). The mitochondria in the extraocular muscles 
show significant changes following BTX-A injection 
in the acute phase (Spencer and McNeer 1987). The 
number of TUNEL-positive nuclei was increased, and 
many nuclei showed condensed chromatin at 2  weeks 
after BTX-A injection. BTX-A application reduces 
Fig. 4 Immunohistochemical findings of Bcl‑2 expression. a The expression of Bcl‑2 was increased in both BTX‑treated groups at 2 weeks after 
injection. The elevated Bcl‑2 expression in the 10 U BTX‑A‑treated group was maintained at 12 weeks after injection (original magnification ×100). 
b The 5 U BTX‑A‑treated group and 10 U BTX‑A‑treated group had significantly higher values compared with the saline‑treated group at 2 weeks 
after injection (*P < 0.05). The 10 U BTX‑A‑treated group had significantly higher values compared with the saline‑treated group at 12 weeks after 
injection (*P < 0.05)
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cellular proliferation in the fibroblasts originating from 
hypertrophic scars (Zhibo and Miaobo 2008). Uncon-
trolled and excessive ER stress will lead to apoptosis 
and cell death (Ron and Walter 2007; Zhang and Kauf-
man 2008b). However, increased TUNEL positive nuclei 
and autophagy formation might not result in complete 
destruction of muscle fibers. As the muscle cell is a multi-
nucleated cell, denervation-induced apoptosis eliminates 
individual nuclei without destroying the entire fiber (Tsai 
et al. 2010). Autophagy formation also increases lifespan 
of affected cells (Lee et al. 2006).
ER stress-induced inflammation is mainly mediated by 
nuclear factor-kappa B (Hu et al. 2006; Zhang and Kauf-
man 2008a). As the expression level of p65 was increased 
by BTX-A injection in this study, ER stress-induced 
inflammation was evident in the BTX-A injected mas-
seter muscle. Accordingly, overexpression of Bcl-2 is 
important in the protection of cells against ER stress-
induced apoptosis (Heath-Engel et  al. 2008). The proa-
poptotic and anti-tumor activity of BTX-A might not 
be related to SNAP-25 (Matak and Lackovic 2015). The 
light chains of BTX-A are mainly localized to the plasma 
membrane in non-neuronal cell lines (Fernández-Salas 
et al. 2004) and might impair mitochondrial respiration. 
This mechanism might also be related to the changes fol-
lowing BTX-A injection in the acute phase. The exact 
mechanism has yet to be elucidated.
Immobility of the skeletal muscle, such as BTX-A 
mediated paralysis, triggers the unfolded protein 
response and increases subsequent ER stress (Alibego-
vic et  al. 2010). ER stress can accumulate in the non-
pathological skeletal muscle (Deldicque et  al. 2012). 
Aberrations in mitochondrial cristae morphology and 
mitochondrial enlargement were evident at 12  weeks 
after BTX-A injection. However, most mitochondria 
had intact outer membranes. Bcl-2 family members 
have a pivotal role in the control of mitochondrial apop-
tosis (Shariat et  al. 2005). Bcl-2 and Bcl-xL protect the 
cell from apoptosis, but Bax induces apoptosis (Shariat 
et  al. 2005). Interestingly, the level of Bcl-2 expression 
was still significantly increased at 12  weeks after 10 U 
BTX-A injection. The overexpression of Bcl-2 can delay 
mitochondrial apoptosis (Shariat et  al. 2005). There-
fore, the intact mitochondrial outer membrane might 
be due to the protective function of Bcl-2. In neurec-
tomy, the expression of cytochrome c, which is released 
Fig. 5 Analysis of TEM of muscular tissue 2 weeks after BTX‑A or saline injection. Shrunken nuclei with chromatin condensation (Nu) was evident in 
both BTX‑A‑treated groups. Swollen mitochondria (Mt) with aberrant cristae were sporadically found. Mitochondria with aberrant cristae (Mt) in the 
10 U BTX‑A‑treated group was encompassed by membranes and underwent autophagy formation
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when rupturing the mitochondrial outer membrane, is 
decreased (Davatz et al. 2007).
Conclusion
Collectively, BTX-A injection induced immobilization of 
the masseter muscle seemed to increase apoptotic stress 
in the masseter muscle via ER stress-induced inflamma-
tion. Overexpression of Bcl-2 might protect muscle cells 
from BTX-A induced apoptotic stress.
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